3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Ovarian Neoplasms
1
Lung Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Interventions
Bevacizumab
40
Paclitaxel
35
Carboplatin
28
pembrolizumab
21
Cyclophosphamide
15
Specimen Handling
14
Cisplatin
13
olaparib
11
Blood Specimen Collection
11
niraparib
10
fludarabine
10
Magnetic Resonance Spectroscopy
9
Drug Therapy
9
liposomal doxorubicin
8
Topotecan
8
Taxes
8
Gemcitabine
8
Biopsy
8
Fulvestrant
7
Doxorubicin
6
cemiplimab
5
abemaciclib
5
Surveys and Questionnaires
5
Standard of Care
5
Injections
5
Fluorouracil
5
Cytoreduction Surgical Procedures
5
trastuzumab deruxtecan
4
mirvetuximab soravtansine
4
aldesleukin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Ovarian Neoplasms
×
Histamine Antagonists
×
Clear all
NCT06824467
2026-05-29
TroFuse-022
Merck Sharp & Dohme LLC
Phase 3
Recruiting
770 enrolled